To develop an orally available small molecule antiviral drug, with treatment of yellow fever virus infection as the primary indication.
Active Definitive Contract Awarded Last action
- Contract number
- 75N93023C00003
- Awardee
-
Baruch S. Blumberg Institute UEI NAYCKSJB7F68
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $16,240,850
Award facts
- Opportunity
-
- 2022 NIAID Omnibus Broad Agency Announcement Pre-Solicitation · BAA20221 · Posted Jan 4, 2022
- Contract value 50% obligated
-
- $16,240,850.00 Current, with exercised options
- $32,348,261.00 Potential, with all options
- Completion date 79% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 10 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Doylestown, PA 18901, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $3,760,574 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $4,983,057 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $2,003,343 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $5,493,876 |
Show all 12
About this award
The National Institute of Allergy and Infectious Diseases awarded a $32.3 million cost-plus-fixed-fee definitive contract to Baruch S. Blumberg Institute on November 15, 2022, to develop an orally available small molecule antiviral drug for treatment of yellow fever virus infection as the primary indication.
Place of performance is Doylestown, PA. The contract carries ultimate completion by November 30, 2027. The originating solicitation was a Broad Agency Announcement from NIAID issued January 4, 2022, seeking proposals for vaccine candidates, therapeutics, and diagnostics for biodefense, antimicrobial resistant infections, and emerging infectious diseases. The announcement targeted directly-acting antivirals for pandemic viruses and related therapeutic research areas within NAICS codes 541711, 541712, and 541710. Utah State University is named as a subcontractor supporting the drug discovery initiative.
Quick answers
Who was awarded contract 75N93023C00003?
75N93023C00003 was awarded to Baruch S. Blumberg Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on November 15, 2022.
How much is contract 75N93023C00003 worth?
The government has obligated $16,240,850 on 75N93023C00003. Its potential value, with all options, is $32,348,261.
Was contract 75N93023C00003 competed?
The extent of competition for 75N93023C00003 was full and open competition. The government received 10 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award